You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
力生製藥(002393.SZ):擬終止原超募資金投資項目“23價肺炎球菌多糖疫苗項目”
格隆匯 12-29 20:23

格隆匯 12 月 29日丨力生製藥(002393.SZ)公佈,公司20201228日召開第六屆董事會第二十二次會議和公司第六屆監事會第二十次會議審議通過了《關於終止全資子公司生化製藥23價肺炎球菌多糖疫苗項目的議案》,公司擬終止原超募資金投資項目23價肺炎球菌多糖疫苗項目

截至20201130日,該項目已使用募集資金16248萬元。

公司持續跟蹤分析項目進展情況,基於對項目目前研發進展研判,結合向國家藥品監督管理局藥品審評中心(CDE)提出溝通交流會議申請而收到的反饋意見研究評估,認為項目原預期結果難以達成。為了降低公司的投資風險,公司本着審慎投資的原則,根據目前客觀實際情況決定終止該項目。

公司終止該項目,並基於當前條件和謹慎性原則對項目相關資產進行減值測試。根據初步估計,本年將對相關資產計提減值準備約6000萬元,該項減值損失計入公司2020度合併損益,相應公司2020年度合併報表歸屬於母公司所有者的淨利潤減少約6000萬元,最終數據以會計師事務所審計的財務數據為準。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account